Longeveron INC. (LGVN) — SEC Filings

Overview

Longeveron INC. (LGVN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a D filed on Mar 25, 2026: Longeveron Inc. filed a Form D on March 25, 2026, indicating a notice of an exempt offering of securities. This filing, under the Securities Act of 1933, suggests Longeveron is raising capital without a full SEC registration, likely through a private placement. For investors, this means the company

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 4 bearish, 44 neutral, 2 mixed. The dominant filing sentiment for Longeveron INC. is neutral.

Filing Type Overview

Longeveron INC. (LGVN) has filed 1 EFFECT, 1 D, 25 8-K, 6 10-Q, 5 S-1/A, 4 S-1, 2 DEF 14A, 1 10-K, 1 SC 13G/A, 2 SC 13G, 1 SC 13D/A, 1 10-K/A with the SEC between Mar 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• EFFECT Filing — EFFECT · Apr 20, 2026
• Longeveron Files Form D for Exempt Securities Offering — D · Mar 25, 2026
  Longeveron Inc. filed a Form D on March 25, 2026, indicating a notice of an exempt offering of securities. This filing, under the Securities Act of 1933, sugges
• Longeveron Inc. Announces Board Changes and CMO Departure — 8-K · Nov 12, 2025 Risk: medium
  Longeveron Inc. announced on November 7, 2025, the departure of its Chief Medical Officer, Dr. Anthony D. D'Souza. The company also reported the election of two
• Longeveron Inc. Files 8-K on Financials — 8-K · Nov 4, 2025 Risk: low
  Longeveron Inc. filed an 8-K on November 4, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and e
• Longeveron's Losses Widen Amid Revenue Drop, Cash Dwindles — 10-Q · Nov 4, 2025 Risk: high
  Longeveron Inc. (LGVN) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $17.26 million, up from $11.89 million
• Longeveron Inc. Reports Director/Officer Changes & Financials — 8-K · Oct 1, 2025 Risk: medium
  Longeveron Inc. filed an 8-K on October 1, 2025, reporting events as of September 25, 2025. The filing pertains to the departure of directors or certain officer
• Longeveron Faces Delisting Concerns — 8-K · Sep 26, 2025 Risk: high
  Longeveron Inc. filed an 8-K on September 26, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The filing indicates a poten
• Longeveron Inc. Files 8-K for Material Agreement — 8-K · Sep 19, 2025 Risk: medium
  Longeveron Inc. filed an 8-K on September 19, 2025, reporting the entry into a material definitive agreement and filing financial statements and exhibits. The f
• Longeveron Inc. Files 8-K on Officer/Director Changes & Financials — 8-K · Sep 3, 2025 Risk: medium
  Longeveron Inc. filed an 8-K on September 3, 2025, reporting on events that occurred on August 27, 2025. The filing pertains to the departure of directors or ce
• Longeveron Inc. Files 8-K on Financials — 8-K · Aug 13, 2025 Risk: low
  Longeveron Inc. filed an 8-K on August 13, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibits. T
• Longeveron's Losses Widen, Cash Dwindles Amid R&D Ramp-Up — 10-Q · Aug 13, 2025 Risk: high
  Longeveron Inc. reported a net loss of $10.0 million for the six months ended June 30, 2025, a significant increase from the $7.5 million net loss for the same
• Longeveron Inc. Files 8-K: Material Agreement & Financials — 8-K · Aug 11, 2025 Risk: medium
  Longeveron Inc. announced on August 8, 2025, the entry into a material definitive agreement. The company also filed financial statements and exhibits as part of
• Longeveron Files S-1/A for Continuous Offering, Signaling Future Capital Raise — S-1/A · Aug 8, 2025 Risk: medium
  Longeveron Inc. (LGVN) filed an S-1/A on August 8, 2025, for a delayed or continuous offering of securities, indicating a strategic move to secure future capita
• Longeveron Files S-1 for Continuous Offering, Signaling Capital Raise — S-1 · Aug 4, 2025 Risk: medium
  Longeveron Inc. filed an S-1 registration statement on August 4, 2025, for a delayed or continuous offering of securities under Rule 415, indicating a strategic
• Longeveron Inc. Files 8-K Reporting Other Events — 8-K · Jul 9, 2025 Risk: low
  Longeveron Inc. filed an 8-K on July 9, 2025, reporting other events and financial statements as of July 8, 2025. The company, incorporated in Delaware, is base
• Longeveron Inc. Files 8-K on Shareholder Votes and Financials — 8-K · Jun 16, 2025 Risk: low
  Longeveron Inc. filed an 8-K on June 13, 2025, reporting on the submission of matters to a vote of security holders and financial statements. The filing details
• Longeveron Inc. Files 8-K on Financials — 8-K · May 8, 2025 Risk: low
  Longeveron Inc. filed an 8-K on May 8, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibi
• Longeveron Inc. Files Q1 2025 10-Q, Details Offerings — 10-Q · May 8, 2025 Risk: medium
  Longeveron Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial position, including common stock and additional paid-
• Longeveron Inc. Shuffles Leadership and Board — 8-K · May 1, 2025 Risk: medium
  Longeveron Inc. announced on April 24, 2025, the departure of Dr. Paul L. Kaloostian as Chief Medical Officer and the appointment of Dr. Joshua M. Hare as inter
• Longeveron Inc. Files Definitive Proxy Statement — DEF 14A · Apr 28, 2025 Risk: medium
  Longeveron Inc. filed its definitive proxy statement on April 28, 2025, for its annual meeting on June 13, 2025. The company, focused on pharmaceutical preparat
• Longeveron Changes Independent Auditor to Marcum LLP — 8-K · Mar 14, 2025 Risk: low
  Longeveron Inc. filed an 8-K on March 13, 2025, to report a change in its certifying accountant. The company has appointed Marcum LLP as its new independent reg
• Longeveron Inc. Files 8-K for FY 2024 Results — 8-K · Feb 28, 2025 Risk: medium
  Longeveron Inc. filed an 8-K on February 28, 2025, reporting its financial results for the fiscal year ending December 31, 2024. The filing details the company'
• Longeveron Inc. Files 2024 10-K Report — 10-K · Feb 28, 2025 Risk: medium
  Longeveron Inc. filed its 2024 10-K report on February 28, 2025, detailing its fiscal year ending December 31, 2024. The company, based in Miami, FL, operates i
• Longeveron Appoints New CMO, Adds Director — 8-K · Jan 30, 2025 Risk: medium
  Longeveron Inc. announced on January 27, 2025, the appointment of Dr. Geoff Thea as Chief Medical Officer and the election of Dr. R. Scott Nolen to its Board of
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Longeveron Inc. Files 8-K on Financials — 8-K · Nov 12, 2024 Risk: low
  Longeveron Inc. filed an 8-K on November 12, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and
• Longeveron Inc. Files Q3 2024 10-Q — 10-Q · Nov 12, 2024 Risk: medium
  Longeveron Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results and provided updates on its business operations.
• Longeveron Inc. Files Q2 2024 10-Q Report — 10-Q · Aug 14, 2024 Risk: medium
  Longeveron Inc. filed its quarterly report for the period ending June 30, 2024. The company, focused on pharmaceutical preparations, reported its financial stat
• Longeveron Inc. Files S-1 Registration Statement — S-1 · Aug 6, 2024 Risk: medium
  Longeveron Inc. filed an S-1 registration statement on August 6, 2024, for its securities. The company, incorporated in Delaware and headquartered in Miami, Flo
• SC 13G Filing — SC 13G · Jul 26, 2024
• Longeveron Inc. Files 8-K: Material Agreement & Equity Sales — 8-K · Jul 19, 2024 Risk: medium
  Longeveron Inc. announced on July 18, 2024, that it entered into a Material Definitive Agreement. The company also reported on unregistered sales of equity secu
• Longeveron Inc. Files 8-K for Other Events — 8-K · Jul 17, 2024 Risk: medium
  Longeveron Inc. filed an 8-K on July 17, 2024, to report other events and financial statements. The filing does not contain specific details about new events or
• Longeveron Inc. Files 8-K for Other Events — 8-K · Jul 10, 2024 Risk: low
  Longeveron Inc. filed an 8-K on July 10, 2024, to report other events and financial statements. The filing does not detail specific transactions or financial re
• Longeveron Inc. Files 8-K on Shareholder Votes and Financials — 8-K · Jul 3, 2024 Risk: low
  Longeveron Inc. filed an 8-K on July 3, 2024, reporting on a submission of matters to a vote of security holders and financial statements. The filing date for t
• Longeveron Inc. Files S-1 Registration Statement — S-1 · Jun 28, 2024 Risk: medium
  Longeveron Inc. filed an S-1 registration statement on June 28, 2024, for an unspecified offering. The company, incorporated in Delaware, is based in Miami, Flo
• Longeveron Inc. Files 8-K for Material Agreement — 8-K · Jun 18, 2024 Risk: medium
  Longeveron Inc. announced on June 17, 2024, that it entered into a Material Definitive Agreement. The company also disclosed unregistered sales of equity securi
• Longeveron Inc. Amends S-1 Registration Filing — S-1/A · May 21, 2024 Risk: medium
  Longeveron Inc. filed an S-1/A amendment on May 21, 2024, related to its registration statement (No. 333-278995). The company, based in Miami, Florida, is invol
• Longeveron Inc. Files Definitive Proxy Statement — DEF 14A · May 20, 2024 Risk: low
  Longeveron Inc. filed its definitive proxy statement on May 20, 2024, for its annual meeting on July 2, 2024. The company, focused on pharmaceutical preparation
• Longeveron Inc. Files 10-Q for Period Ended March 31, 2024 — 10-Q · May 14, 2024 Risk: low
  Longeveron Inc. (LGVN) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Longeveron Inc. filed a 10-Q report for the quarterly period ended March 31
• Longeveron Inc. Faces Delisting Concerns — 8-K · May 10, 2024 Risk: high
  Longeveron Inc. filed an 8-K on May 10, 2024, reporting a notice of delisting or failure to satisfy continued listing rules, along with changes in directors and
• Longeveron Inc. Files S-1 Registration Statement — S-1 · Apr 30, 2024 Risk: low
  Longeveron Inc. (LGVN) filed a IPO Registration (S-1) with the SEC on April 30, 2024. Longeveron Inc. filed an S-1 registration statement with the SEC on April
• Longeveron Raises $1M in Stock and Warrant Sale — 8-K · Apr 18, 2024 Risk: medium
  Longeveron Inc. announced on April 16, 2024, that it entered into a Securities Purchase Agreement with an accredited investor for the sale of 1,000,000 shares o
• SC 13G Filing — SC 13G · Apr 17, 2024
• Longeveron Inc. Files Amendment No. 1 to S-1 Registration Statement — S-1/A · Apr 16, 2024 Risk: low
  Longeveron Inc. (LGVN) filed a Amended IPO Registration (S-1/A) with the SEC on April 16, 2024. Longeveron Inc. filed an Amendment No. 1 to its Form S-1 Registr
• Hare Amends Longeveron Stake Filing — SC 13D/A · Apr 15, 2024 Risk: medium
  Joshua M. Hare, M.D. has amended his Schedule 13D filing for Longeveron Inc. on April 10, 2024. The filing indicates a change in the beneficial ownership of the
• Longeveron Inc. Files 8-K: Material Definitive Agreement — 8-K · Apr 11, 2024 Risk: medium
  Longeveron Inc. announced on April 8, 2024, that it entered into a Material Definitive Agreement. The filing also includes other events and financial statements
• Longeveron Inc. Files S-1/A Amendment — S-1/A · Apr 5, 2024 Risk: medium
  Longeveron Inc. filed an S-1/A amendment on April 5, 2024, for its registration statement. The company, located in Miami, Florida, is in the pharmaceutical prep
• Longeveron Inc. Files Amendment No. 1 to S-1 Registration Statement — S-1/A · Apr 3, 2024 Risk: low
  Longeveron Inc. (LGVN) filed a Amended IPO Registration (S-1/A) with the SEC on April 3, 2024. Longeveron Inc. filed an amendment to its S-1 registration statem
• Longeveron Files 8-K with Bylaw Amendments & Exhibits — 8-K · Mar 19, 2024 Risk: low
  Longeveron Inc. filed an 8-K on March 19, 2024, reporting amendments to its articles of incorporation or bylaws, a Regulation FD disclosure, and financial state
• Longeveron Inc. Files Amendment to Annual Report on Form 10-K — 10-K/A · Mar 11, 2024 Risk: low
  Longeveron Inc. (LGVN) filed a Amended Annual Report (10-K/A) with the SEC on March 11, 2024. Longeveron Inc. filed an amendment (Amendment No. 1) to its annual

Risk Profile

Risk Assessment: Of LGVN's 45 recent filings, 4 were flagged as high-risk, 25 as medium-risk, and 16 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Longeveron INC.'s most recent 10-Q filing (Nov 4, 2025):

• Revenue: $0.83M
• Net Income: -$17.26M
• EPS: N/A
• Debt-to-Equity: 0.56
• Cash Position: $9.24M
• Operating Margin: -2145.5%
• Total Assets: $15.56M
• Total Debt: $5.59M

Key Executives

• Dr. Anthony D. D'Souza
• Dr. David L. Katz
• Mr. David M. S. Kim
• Hypoplastic Left Heart Syndrome
• Wa’el Hashad
• Jennifer Minter, Esq.
• Adam G. Wicks, Esq.
• Rick A. Werner, Esq.
• Jayun Koo, Esq.
• Wa'el Hashad
• Dr. Paul L. Kaloostian
• Dr. Joshua M. Hare
• Ms. Karen M. Smith
• Dr. Geoff Thea
• Dr. R. Scott Nolen

Industry Context

Longeveron operates in the highly competitive and capital-intensive biotechnology sector, focusing on regenerative medicine. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Success hinges on groundbreaking scientific innovation, successful clinical trials, and securing substantial funding to navigate the path to market approval.

Top Tags

SEC Filing (7) · 8-k (6) · sec-filing (6) · management-change (5) · filing (5) · financial-reporting (5) · Biotechnology (4) · corporate-governance (4) · material-agreement (4) · financials (4)

Key Numbers

• Net Loss: $17.26M — for the nine months ended September 30, 2025, up from $11.89M in 2024
• Total Revenues: $0.83M — for the nine months ended September 30, 2025, down from $1.79M in 2024
• Cash and Cash Equivalents: $9.24M — as of September 30, 2025, down from $19.23M at December 31, 2024
• Accumulated Deficit: $126.9M — as of September 30, 2025
• Research and Development Expenses: $9.32M — for the nine months ended September 30, 2025, up from $6.15M in 2024
• General and Administrative Expenses: $9.11M — for the nine months ended September 30, 2025, up from $7.45M in 2024
• Cash Runway: Q1 2026 — anticipated funding period for existing cash and cash equivalents
• At-The-Market (ATM) Facility: $10.7M — aggregate market value of shares available for sale
• Total Operating Expenses: $11.0M — for six months ended June 30, 2025, up from $8.3M in 2024
• Class A Common Stock Shares Outstanding: 13,694,570 — as of August 8, 2025
• Registration Number: 333-289210 — Identifies the specific S-1/A filing for Longeveron Inc.
• Filing Date: 2025-08-08 — Date Longeveron Inc. filed Amendment No. 1 to Form S-1.
• SIC Code: 2834 — Primary Standard Industrial Classification Code for Pharmaceutical Preparations, indicating Longeveron's industry.
• Business Phone: 305-909-0840 — Contact number for Longeveron Inc.'s principal executive offices.
• SEC File Number: 333-289210 — Unique identifier for Longeveron Inc.'s S-1 registration statement

Frequently Asked Questions